StemCell Therapy

The science of indirectly manipulating an organism's genes using techniques like molecular cloning and transformation to alter the structure and nature of genes is called genetic engineering. Genetic engineering can bring about a great amount of transformation in the characteristics of an organism by the manipulation of DNA, which is like the code inscribed in every cell determining how it functions. Like any other science, genetic engineering also has pros and cons. Let us look at some of them.

Pros of Genetic Engineering

Better Taste, Nutrition and Growth Rate Crops like potato, tomato, soybean and rice are currently being genetically engineered to obtain new strains with better nutritional qualities and increased yield. The genetically engineered crops are expected to have the capacity to grow on lands that are presently not suitable for cultivation. The manipulation of genes in crops is expected to improve their nutritional value as also their rate of growth. Biotechnology, the science of genetically engineering foods, can be used to impart a better taste to food.

Pest-resistant Crops and Longer Shelf life Engineered seeds are resistant to pests and can survive in relatively harsh climatic conditions. The plant gene At-DBF2, when inserted in tomato and tobacco cells is seen to increase their endurance to harsh soil and climatic conditions. Biotechnology can be used to slow down the process of food spoilage. It can thus result in fruits and vegetables that have a greater shelf life.

Genetic Modification to Produce New Foods Genetic engineering in food can be used to produce totally new substances such as proteins and other food nutrients. The genetic modification of foods can be used to increase their medicinal value, thus making homegrown edible vaccines available.

Modification of Genetic Traits in Humans Genetic engineering has the potential of succeeding in case of human beings too. This specialized branch of genetic engineering, which is known as human genetic engineering is the science of modifying genotypes of human beings before birth. The process can be used to manipulate certain traits in an individual.

Boost Positive Traits, Suppress Negative Ones Positive genetic engineering deals with enhancing the positive traits in an individual like increasing longevity or human capacity while negative genetic engineering deals with the suppression of negative traits in human beings like certain genetic diseases. Genetic engineering can be used to obtain a permanent cure for dreaded diseases.

Modification of Human DNA If the genes responsible for certain exceptional qualities in individuals can be discovered, these genes can be artificially introduced into genotypes of other human beings. Genetic engineering in human beings can be used to change the DNA of individuals to bring about desirable structural and functional changes in them.

Cons of Genetic Engineering

May Hamper Nutritional Value Genetic engineering in food involves the contamination of genes in crops. Genetically engineered crops may supersede natural weeds. They may prove to be harmful for natural plants. Undesirable genetic mutations can lead to allergies in crops. Some believe that genetic engineering in foodstuffs can hamper their nutritional value while enhancing their taste and appearance.

View post:
Pros and Cons of Genetic Engineering - Buzzle

What is genetic engineering? Genetic engineering is the process of manually adding new DNA to an organism. The goal is to add one or more new traits that are not already found in that organism. Examples of genetically engineered (transgenic) organisms currently on the market include plants with resistance to some insects, plants that can tolerate herbicides, and crops with modified oil content.

Understanding Genetic Engineering: Basic Biology To understand how genetic engineering works, there are a few key biology concepts that must be understood.

Small segments of DNA are called genes. Each gene holds the instructions for how to produce a single protein. This can be compared to a recipe for making a food dish. A recipe is a set of instructions for making a single dish.

An organism may have thousands of genes. The set of all genes in an organism is called a genome. A genome can be compared to a cookbook of recipes that makes that organism what it is. Every cell of every living organism has a cookbook.

CONCEPT #2: Why are proteins important? Proteins do the work in cells. They can be part of structures (such as cell walls, organelles, etc). They can regulate reactions that take place in the cell. Or they can serve as enzymes, which speed-up reactions. Everything you see in an organism is either made of proteins or the result of a protein action.

How is genetic engineering done? Genetic engineering, also called transformation, works by physically removing a gene from one organism and inserting it into another, giving it the ability to express the trait encoded by that gene. It is like taking a single recipe out of a cookbook and placing it into another cookbook.

1) First, find an organism that naturally contains the desired trait.

2) The DNA is extracted from that organism. This is like taking out the entire cookbook.

3) The one desired gene (recipe) must be located and copied from thousands of genes that were extracted. This is called gene cloning.

4) The gene may be modified slightly to work in a more desirable way once inside the recipient organism.

Follow this link:
UNL's AgBiosafety for Educators

Genetic engineering is a set of technologies used to change the genetic makeup of cells, including thetransfer of genes within and across species boundaries to produce improved or novel organisms. The techniques involve sophisticated manipulations of genetic material and other biologically important chemicals.

Genes are the chemical blueprints that determine an organism's traits. Moving genes from one organism to another transfers those traits. Through genetic engineering, organisms can be given targeted combinations of new genesand therefore new combinations of traitsthat do not occur in nature and, indeed, cannot be developed by natural means. Such an approach is different from classical plant and animal breeding, which operates through selection across many generations for traits of interest. Classical breeding operates on traits, only indirectly selecting genes, whereas biotechnology targets genes, attempting to influence traits. The potential of biotechnology is to rapidly accelerate the rate of progress and efficiency of breeding.

Novel organisms

Nature can produce organisms with new gene combinations through sexual reproduction. A brown cow bred to a yellow cow may produce a calf of a completely new color. But reproductive mechanisms limit the number of new combinations. Cows must breed with other cows (or very near relatives). A breeder who wants a purple cow would be able to breed toward one only if the necessary purple genes were available somewhere in a cow or a near relative to cows. A genetic engineer has no such restriction. If purple genes are available anywhere in naturein a sea urchin or an iristhose genes could be used in attempts to produce purple cows. This unprecedented ability to shuffle genes means that genetic engineers can concoct gene combinations that would never be found in nature.

New risks

Genetic engineering is therefore qualitatively different from existing breeding technologies. It is a set of technologies for altering the traits of living organisms by inserting genetic material that has been manipulated to extract it from its source and successfully insert it in functioning order in target organisms. Because of this, genetic engineering may one day lead to the routine addition of novel genes that have been wholly synthesized in the laboratory.

In addition to desired benefits, novel organisms may bring novel risks as well. These risks must be carefully assessed to make sure that all effectsboth desired and unintendedare benign. UCS advocates caution, examination of alternatives, and careful, contextual, case-by-case evaluation of genetic enginering applications within an overall framework that moves agricultural systems of food production toward sustainability.

Here is the original post:
What Is Genetic Engineering? | Union of Concerned Scientists

While scientific progress on molecular biology has a great potential to increase our understanding of nature and provide new medical tools, it should not be used as justification to turn the environment into a giant genetic experiment by commercial interests. The biodiversity and environmental integrity of the world's food supply is too important to our survival to be put at risk. What's wrong with genetic engineering (GE)?

Genetic engineering enables scientists to create plants, animals and micro-organisms by manipulating genes in a way that does not occur naturally.

These genetically modified organisms (GMOs) can spread through nature and interbreed with natural organisms, thereby contaminating non 'GE' environments and future generations in an unforeseeable and uncontrollable way.

Their release is 'genetic pollution' and is a major threat because GMOs cannot be recalled once released into the environment.

Because of commercial interests, the public is being denied the right to know about GE ingredients in the food chain, and therefore losing the right to avoid them despite the presence of labelling laws in certain countries.

Biological diversity must be protected and respected as the global heritage of humankind, and one of our world's fundamental keys to survival. Governments are attempting to address the threat of GE with international regulations such as the Biosafety Protocol.

April 2010: Farmers, environmentalists and consumers from all over Spain demonstrate in Madrid under the slogan "GMO-free agriculture." They demand the Government to follow the example of countries like France, Germany or Austria, and ban the cultivation of GM maize in Spain.

GMOs should not be released into the environment since there is not an adequate scientific understanding of their impact on the environment and human health.

We advocate immediate interim measures such as labelling of GE ingredients, and the segregation of genetically engineered crops and seeds from conventional ones.

We also oppose all patents on plants, animals and humans, as well as patents on their genes. Life is not an industrial commodity. When we force life forms and our world's food supply to conform to human economic models rather than their natural ones, we do so at our own peril.

Read more:
Genetic Engineering | Greenpeace International

During the latter stage stages of the 20th century, man harnessed the power of the atom, and not long after, soon realised the power of genes. Genetic engineering is going to become a very mainstream part of our lives sooner or later, because there are so many possibilities advantages (and disadvantages) involved. Here are just some of the advantages :

Of course there are two sides to the coin, here are some possible eventualities and disadvantages.

Genetic engineering may be one of the greatest breakthroughs in recent history alongside the discovery of the atom and space flight, however, with the above eventualities and facts above in hand, governments have produced legislation to control what sort of experiments are done involving genetic engineering. In the UK there are strict laws prohibiting any experiments involving the cloning of humans. However, over the years here are some of the experimental 'breakthroughs' made possible by genetic engineering.

Genetic engineering has been impossible until recent times due to the complex and microscopic nature of DNA and its component nucleotides. Through progressive studies, more and more in this area is being made possible, with the above examples only showing some of the potential that genetic engineering shows.

For us to understand chromosomes and DNA more clearly, they can be mapped for future reference. More simplistic organisms such as fruit fly (Drosophila) have been chromosome mapped due to their simplistic nature meaning they will require less genes to operate. At present, a task named the Human Genome Project is mapping the human genome, and should be completed in the next ten years.

The process of genetic engineering involves splicing an area of a chromosome, a gene, that controls a certain characteristic of the body. The enzyme endonuclease is used to split a DNA sequence and split the gene from the rest of the chromosome. For example, this gene may be programmed to produce an antiviral protein. This gene is removed and can be placed into another organism. For example, it can be placed into a bacteria, where it is sealed into the DNA chain using ligase. When the chromosome is once again sealed, the bacteria is now effectively re-programmed to replicate this new antiviral protein. The bacteria can continue to live a healthy life, though genetic engineering and human intervention has actively manipulated what the bacteria actually is. No doubt there are advantages and disadvantages, and this whole subject area will become more prominent over time.

The next page returns the more natural circumstances of genetic diversity.

See the original post:
Genetic Engineering Advantages & Disadvantages - Biology ...

Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient's cells as a drug to treat disease. The polymers are either expressed as proteins, interfere with protein expression, or possibly correct genetic mutations.

The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a "vector", which carries the molecule inside cells.

Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies. The first gene therapy experiment approved by the US Food and Drug Administration (FDA) occurred in 1990, when Ashanti DeSilva was treated for ADA-SCID.[1] By January 2014, some 2,000 clinical trials had been conducted or approved.[2]

Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers' attention, although as of 2014, it was still largely an experimental technique.[3] These include treatment of retinal disease Leber's congenital amaurosis,[4][5][6][7]X-linked SCID,[8] ADA-SCID,[9][10]adrenoleukodystrophy,[11]chronic lymphocytic leukemia (CLL),[12]acute lymphocytic leukemia (ALL),[13]multiple myeloma,[14]haemophilia[10] and Parkinson's disease.[15] Between 2013 and April 2014, US companies invested over $600 million in the field.[16]

The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers.[17] In 2012 Glybera, a treatment for a rare inherited disorder, became the treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.[3][18]

Following early advances in genetic engineering of bacteria, cells and small animals, scientists started considering how to apply it to medicine. Two main approaches were considered replacing or disrupting defective genes.[19] Scientists focused on diseases caused by single-gene defects, such as cystic fibrosis, haemophilia, muscular dystrophy, thalassemia and sickle cell anemia. Glybera treats one such disease, caused by a defect in lipoprotein lipase.[18]

DNA must be administered, reach the damaged cells, enter the cell and express/disrupt a protein.[20] Multiple delivery techniques have been explored. The initial approach incorporated DNA into an engineered virus to deliver the DNA into a chromosome.[21][22]Naked DNA approaches have also been explored, especially in the context of vaccine development.[23]

Generally, efforts focused on administering a gene that causes a needed protein to be expressed. More recently, increased understanding of nuclease function has led to more direct DNA editing, using techniques such as zinc finger nucleases and CRISPR. The vector incorporates genes into chromosomes. The expressed nucleases then "edit" the chromosome. As of 2014 these approaches involve removing cells from patients, editing a chromosome and returning the transformed cells to patients.[24]

Other technologies employ antisense, small interfering RNA and other DNA. To the extent that these technologies do not alter DNA, but instead directly interact with molecules such as RNA, they are not considered "gene therapy" per se.[citation needed]

Gene therapy may be classified into two types:

See the rest here:
Gene therapy - Wikipedia, the free encyclopedia

Written by Patrick Dixon

Futurist Keynote Speaker: Posts, Slides, Videos - Biotechnology, Genetics, Gene Therapy, Stem Cells

Genetic engineering is the alteration of genetic code by artificial means, and is therefore different from traditional selective breeding.

Genetic engineering examples include taking the gene that programs poison in the tail of a scorpion, and combining it with a cabbage. These genetically modified cabbages kill caterpillers because they have learned to grow scorpion poison (insecticide) in their sap.

Genetic engineering also includes insertion of human genes into sheep so that they secrete alpha-1 antitrypsin in their milk - a useful substance in treating some cases of lung disease.

Genetic engineering has created a chicken with four legs and no wings.

Genetic engineering has created a goat with spider genes that creates "silk" in its milk.

Genetic engineering works because there is one language of life: human genes work in bacteria, monkey genes work in mice and earthworms. Tree genes work in bananas and frog genes work in rice. There is no limit in theory to the potential of genetic engineering.

Genetic engineering has given us the power to alter the very basis of life on earth.

Genetic engineering has been said to be no different than ancient breeding methods but this is untrue. For a start, breeding or cross-breeding, or in-breeding (for example to make pedigree dogs) all work by using the same species. In contrast genetic engineering allows us to combine fish, mouse, human and insect genes in the same person or animal.

Read the original:
Genetic Engineering : What is Genetic Engineering

Genetic engineering (GE) is the modification of an organisms genetic composition by artificial means, often involving the transfer of specific traits, or genes, from one organism into a plant or animal of an entirely different species. When gene transfer occurs, the resulting organism is called transgenic or a GMO (genetically modified organism).

Genetic engineering is different from traditional cross breeding, where genes can only be exchanged between closely related species. With genetic engineering, genes from completely different species can be inserted into one another. For example, scientists in Taiwan have successfully inserted jellyfish genes into pigs in order to make them glow in the dark.

All life is made up of one or more cells. Each cell contains a nucleus, and inside each nucleus are strings of molecules called DNA (deoxyribonucleic acid). Each strand of DNA is divided into small sections called genes. These genes contain a unique set of instructions that determine how the organism grows, develops, looks, and lives.

During genetic engineering processes, specific genes are removed from one organism and inserted into another plant or animal, thus transferring specific traits.

Nearly 400 million acres of farmland worldwide are now used to grow GE crops such as cotton, corn, soybeans and rice. In the United States, GE soybeans, corn and cotton make up 93%, 88% and 94% of the total acreage of the respective crops. The majority of genetically engineered crops grown today are engineered to be resistant to pesticides and/or herbicides so that they can withstand being sprayed with weed killer while the rest of the plants in the field die.

GE proponents claim genetically engineered crops use fewer pesticides than non-GE crops, when in reality GE plants can require even more chemicals. This is because weeds become resistant to pesticides, leading farmers to spray even more on their crops. This pollutes the environment, exposes food to higher levels of toxins, and creates greater safety concerns for farmers and farm workers.

Some GE crops are actually classified as pesticides. For instance, the New Leaf potato, which has since been taken off grocery shelves, was genetically engineered to produce the Bt (Bacillus thuringiensis) toxin in order to kill any pests that attempted to eat it. The actual potato was designated as a pesticide and was therefore regulated by the Environmental Protection Agency (EPA), instead of the Food & Drug Administration (FDA), which regulates food. Because of this, safety testing for these potatoes was not as rigorous as with food, since the EPA regulations had never anticipated that people would intentionally consume pesticides as food.

Adequate research has not yet been carried out to identify the effects of eating animals that have been fed genetically engineered grain, nor have sufficient studies been conducted on the effects of directly consuming genetically engineered crops like corn and soy. Yet despite our lack of knowledge, GE crops are widely used throughout the world as both human and animal food.

Scientists are currently working on ways to genetically engineer farm animals. Atlantic salmon have been engineered to grow to market size twice as fast as wild salmon, chickens have been engineered so that they cannot spread H5N1 avian flu to other birds, and research is being conducted to create cattle that cannot develop the infectious prions that can cause bovine spongiform encephalopathy (aka mad cow disease). At this point, no GE animals have been approved by the FDA to enter the food supply. Genetic engineering experiments on animals do, however, pose potential risks to food safety and the environment.

In 2003, scientists at the University of Illinois were conducting an experiment that involved inserting cow genes into female pigs in order to increase their milk production. They also inserted a synthetic gene to make milk digestion easier for the piglets. Although the experimental pigs were supposed to be destroyed, as instructed by the FDA, 386 offspring of the experimental pigs were sold to slaughterhouses, where they were processed and sent to grocery stores as pork chops, sausage, and bacon.

Read the original:
Sustainable Table | Genetic Engineering

Genetic engineering, also called genetic modification, is the direct manipulation of an organism's genome using biotechnology. New DNA may be inserted in the host genome by first isolating and copying the genetic material of interest using molecular cloning methods to generate a DNA sequence, or by synthesizing the DNA, and then inserting this construct into the host organism. Genes may be removed, or "knocked out", using a nuclease. Gene targeting is a different technique that uses homologous recombination to change an endogenous gene, and can be used to delete a gene, remove exons, add a gene, or introduce point mutations.

An organism that is generated through genetic engineering is considered to be a genetically modified organism (GMO). The first GMOs were bacteria generated in 1973 and GM mice in 1974. Insulin-producing bacteria were commercialized in 1982 and genetically modified food has been sold since 1994. Glofish, the first GMO designed as a pet, was first sold in the United States December in 2003.[1]

Genetic engineering techniques have been applied in numerous fields including research, agriculture, industrial biotechnology, and medicine. Enzymes used in laundry detergent and medicines such as insulin and human growth hormone are now manufactured in GM cells, experimental GM cell lines and GM animals such as mice or zebrafish are being used for research purposes, and genetically modified crops have been commercialized.

IUPAC definition

Process of inserting new genetic information into existing cells in order to modify a specific organism for the purpose of changing its characteristics.

Note: Adapted from ref.[2][3]

Genetic engineering alters the genetic make-up of an organism using techniques that remove heritable material or that introduce DNA prepared outside the organism either directly into the host or into a cell that is then fused or hybridized with the host.[4] This involves using recombinant nucleic acid (DNA or RNA) techniques to form new combinations of heritable genetic material followed by the incorporation of that material either indirectly through a vector system or directly through micro-injection, macro-injection and micro-encapsulation techniques.

Genetic engineering does not normally include traditional animal and plant breeding, in vitro fertilisation, induction of polyploidy, mutagenesis and cell fusion techniques that do not use recombinant nucleic acids or a genetically modified organism in the process.[4] However the European Commission has also defined genetic engineering broadly as including selective breeding and other means of artificial selection.[5]Cloning and stem cell research, although not considered genetic engineering,[6] are closely related and genetic engineering can be used within them.[7]Synthetic biology is an emerging discipline that takes genetic engineering a step further by introducing artificially synthesized material from raw materials into an organism.[8]

If genetic material from another species is added to the host, the resulting organism is called transgenic. If genetic material from the same species or a species that can naturally breed with the host is used the resulting organism is called cisgenic.[9] Genetic engineering can also be used to remove genetic material from the target organism, creating a gene knockout organism.[10] In Europe genetic modification is synonymous with genetic engineering while within the United States of America it can also refer to conventional breeding methods.[11][12] The Canadian regulatory system is based on whether a product has novel features regardless of method of origin. In other words, a product is regulated as genetically modified if it carries some trait not previously found in the species whether it was generated using traditional breeding methods (e.g., selective breeding, cell fusion, mutation breeding) or genetic engineering.[13][14][15] Within the scientific community, the term genetic engineering is not commonly used; more specific terms such as transgenic are preferred.

Plants, animals or micro organisms that have changed through genetic engineering are termed genetically modified organisms or GMOs.[16] Bacteria were the first organisms to be genetically modified. Plasmid DNA containing new genes can be inserted into the bacterial cell and the bacteria will then express those genes. These genes can code for medicines or enzymes that process food and other substrates.[17][18] Plants have been modified for insect protection, herbicide resistance, virus resistance, enhanced nutrition, tolerance to environmental pressures and the production of edible vaccines.[19] Most commercialised GMO's are insect resistant and/or herbicide tolerant crop plants.[20] Genetically modified animals have been used for research, model animals and the production of agricultural or pharmaceutical products. They include animals with genes knocked out, increased susceptibility to disease, hormones for extra growth and the ability to express proteins in their milk.[21]

View original post here:
Genetic engineering - Wikipedia, the free encyclopedia

genetic engineering,the artificial manipulation, modification, and recombination of DNA or other nucleic acid molecules in order to modify an organism or population of organisms.

The term genetic engineering initially meant any of a wide range of techniques for the modification or manipulation of organisms through the processes of heredity and reproduction. As such, the term embraced both artificial selection and all the interventions of biomedical techniques, among them artificial insemination, in vitro fertilization (e.g., test-tube babies), sperm banks, cloning, and gene manipulation. But the term now denotes the narrower field of recombinant DNA technology, or gene cloning (see Figure), in which DNA molecules from two or more sources are combined either within cells or in vitro and are then inserted into host organisms in which they are able to propagate. Gene cloning is used to produce new genetic combinations that are of value to science, medicine, agriculture, or industry.

DNA is the carrier of genetic information; it achieves its effects by directing the synthesis of proteins. Most recombinant DNA technology involves the insertion of foreign genes into the plasmids of common laboratory strains of bacteria. Plasmids are small rings of DNA; they are not part of the bacteriums chromosome (the main repository of the organisms genetic information). Nonetheless, they are capable of directing protein synthesis, and, like chromosomal DNA, they are reproduced and passed on to the bacteriums progeny. Thus, by incorporating foreign DNA (for example, a mammalian gene) into a bacterium, researchers can obtain an almost limitless number of copies of the inserted gene. Furthermore, if the inserted gene is operative (i.e., if it directs protein synthesis), the modified bacterium will produce the protein specified by the foreign DNA.

A key step in the development of genetic engineering was the discovery of restriction enzymes in 1968 by the Swiss microbiologist Werner Arber. However, type II restriction enzymes, which are essential to genetic engineering for their ability to cleave a specific site within the DNA (as opposed to type I restriction enzymes, which cleave DNA at random sites), were not identified until 1969, when the American molecular biologist Hamilton O. Smith purified this enzyme. Drawing on Smiths work, the American molecular biologist Daniel Nathans helped advance the technique of DNA recombination in 197071 and demonstrated that type II enzymes could be useful in genetic studies. Genetic engineering itself was pioneered in 1973 by the American biochemists Stanley N. Cohen and Herbert W. Boyer, who were among the first to cut DNA into fragments, rejoin different fragments, and insert the new genes into E. coli bacteria, which then reproduced.

Genetic engineering has advanced the understanding of many theoretical and practical aspects of gene function and organization. Through recombinant DNA techniques, bacteria have been created that are capable of synthesizing human insulin, human growth hormone, alpha interferon, a hepatitis B vaccine, and other medically useful substances. Plants may be genetically adjusted to enable them to fix nitrogen, and genetic diseases can possibly be corrected by replacing bad genes with normal ones. Nevertheless, special concern has been focused on such achievements for fear that they might result in the introduction of unfavourable and possibly dangerous traits into microorganisms that were previously free of theme.g., resistance to antibiotics, production of toxins, or a tendency to cause disease.

The new microorganisms created by recombinant DNA research were deemed patentable in 1980, and in 1986 the U.S. Department of Agriculture approved the sale of the first living genetically altered organisma virus, used as a pseudorabies vaccine, from which a single gene had been cut. Since then several hundred patents have been awarded for genetically altered bacteria and plants.

Read the original post:
genetic engineering | Encyclopedia Britannica

Genetic Engineering, Stem Cell Research, and Human Cloning
From:UniversalpptsViews:0 0ratingsTime:01:31More inEducation

See the rest here:
Genetic Engineering, Stem Cell Research, and Human Cloning - Video

Ramble: Simelweis Taboo
I just don #39;t understand narrowmindedness. I don #39;t understand the stubborn refusal to face reality with integrity. I don #39;t understand cowardice. We each have only one life. Why squander it on timidity, prejudice and just so stories? Video referenced: "Taboos of Science" scishow youtu.be " Published on Jul 30, 2012 Hank discusses some of the taboos which have plagued scientific inquiry in the past and a few that still exist today. Like SciShow? http://www.facebook.com Follow SciShow: http://www.twitter.com References: dft.ba This video contains the following sounds from Freesound.org: "grim fart.wav" by Walter_Odington "Toilet Flush.wav" by tweeterdj science, scishow, taboo, society, culture, research, study, ignaz semmelweis, germ theory, disease, louis pasteur, antiseptic, social norms, semmelweis reflex, dean radin, noetic science, stem cell, chimaera, human cloning, clone, dolly, sheep, ethics, religion, panayiotis zavos, synthetic biology, genetic engineering, biology, genetics, mental health, gender identity, gender dysphoria, sexual orientation, physics, archaeology, human remains, spirituality, consciousness, poop, toilet, sanitation"From:rriverstone1Views:33 3ratingsTime:15:28More inPeople Blogs

Follow this link:
Ramble: Simelweis Taboo - Video

Genetic Engineering Of Mesenchymal Stem Cells
ll4.me Genetic Engineering Of Mesenchymal Stem Cells 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G. Wagemaker- 2. Establishment and Transduction of primary human Stromal/Mesenchymal Stem Cell Monolayers; T. Meyerrose, I. Rosova, m. Dao, P. Herrbrich, G. Bauer, JA Nolta- 3. Gene Expression Profiles of Mesenchymal Stem Cells; DG Phinney- 4. In Vivo Homing and Regeneration of freshly isolated and culture Murine Mesenchymal Stem Cells; RE Ploemacher- 5. Non-human primate models of Mesenchymal Stem Cell Transplantation; SM Devine, R. Hoffman- 6. Engineering of Human Adipose-derived Mesenchymal Stem-like Cells; JK Fraser, M. Zhu, B. Strem, MH Hedrick- 7. Uncommitted Progenitors in Cultures of Bone Marrow-derived Mesenchymal Stem Cells; JJ Minguell, A. Rices, WD Sierralta- 8. Bone Marrow Mesenchymal Stem Cell Transplantation for Children with severe Osteogenesis Imperfecta; EM Horwitz, PL Gordon- 9. Clinical Trials of Human Mesenchymal Stem Cells to support Hematopoietic Stem Cell Transplantation; ON Ko EAN/ISBN : 9781402039591 Publisher(s): Springer Netherlands Discussed keywords: Stammzelle Format: ePub/PDF Author(s): Nolta, Jan A. 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G. Wagemaker- 2. Establishment and Transduction of primary human Stromal/Mesenchymal Stem Cell Monolayers; T. MeyerFrom:jonibishop696Views:0 0ratingsTime:00:12More inPeople Blogs

See original here:
Genetic Engineering Of Mesenchymal Stem Cells - Video

Bruce Lipton - New Health Paradigm
upliftfestival.com UPLIFT 2012 is thrilled to bring Bruce Lipton to Byron Bay! Bruce H. Lipton, PhD is an internationally recognized leader in bridging science and spirit. Stem cell biologist, bestselling author of The Biology of Belief and recipient of the 2009 Goi Peace Award, he has been a guest speaker on hundreds of TV and radio shows, as well as keynote presenter for national and international conferences. Dr. Lipton began his scientific career as a cell biologist. He received his Ph.D. Degree from the University of Virginia at Charlottesville before joining the Department of Anatomy at the University of Wisconsin #39;s School of Medicine in 1973. Dr. Lipton #39;s research on muscular dystrophy, studies employing cloned human stem cells, focused upon the molecular mechanisms controlling cell behavior. An experimental tissue transplantation technique developed by Dr. Lipton and colleague Dr. Ed Schultz and published in the journal Science was subsequently employed as a novel form of human genetic engineering. In 1982, Dr. Lipton began examining the principles of quantum physics and how they might be integrated into his understanding of the cell #39;s information processing systems. He produced breakthrough studies on the cell membrane, which revealed that this outer layer of the cell was an organic homologue of a computer chip, the cell #39;s equivalent of a brain. His research at Stanford University #39;s School of Medicine, between 1987 and 1992, revealed that the environment ...From:UPLIFTfestivalTVViews:35 0ratingsTime:02:48More inPeople Blogs

Read more from the original source:
Bruce Lipton - New Health Paradigm - Video

26-Medical BiotechnologySG Part Ic. Animal and Human Cloning and Genetic Engineering.mov
Some of the same techniques described for stem cell research, have been extended and applied to animal cloning, creating part of the controversies surrounding both topics. What is cloning? Cloning an organism (as a totally different process distinguished from cloning a gene) is a process whereby all members are directly descended, asexually, from a single organism by......various ways, as we show in this section, and this demonstrates that all the information required for an organism and its development are in the a single cell. many animals have now been cloned, including, sheep (Dolly), cattle, pigs, mice, rats, fish, dogs, cats, horses, mules, and more recently monkeys. Can humans be cloned? Probably.From:Albert KauschViews:8 0ratingsTime:25:57More inEducation

View post:
26-Medical BiotechnologySG Part Ic. Animal and Human Cloning and Genetic Engineering.mov - Video

Public release date: 17-Oct-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, October 17, 2012SELEX is a rapid, efficient, and iterative high-throughput method for screening large libraries of molecules to identify those with the potential to be developed as drug compounds or research tools. Advances in SELEX technology that have enabled screening in live cells, called Cell-SELEX, are explored in a comprehensive Review article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. The article is available free on the BioResearch Open Access website.

Cell-SELEX uses live cells as targets for binding of molecules called aptamers, comprised of short chains of nucleic acids. Aptamers share many of the qualities that have made antibodies such successful drugs, but offer additional advantages such as stability, short length, and ease of manufacturing. Shoji Ohuchi, University of Tokyo, Japan, examines the ongoing progress in developing and refining this useful process for drug compound screening in the Review article "Cell-SELEX Technology."

"This review summarizes the progress and application of Cell-SELEX technology, providing an excellent resource for beginners to the field and experts alike," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies, Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc. website.

View post:
Progress in Cell-SELEX compound screening technology reviewed in BioResearch Open Access

ST. LOUIS, Oct. 16, 2012 /PRNewswire/ --Sigma-Aldrich Corporation (SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma Life Science, and Ekam Imaging, Inc. have partnered to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology. For more information on SAGE Labs, visit http://www.sageresearchmodels.com.

Unlike the fMRI studies currently performed in drug development that require anesthetized, unconscious animals, Ekam Imaging's fMRI translational technology produces detailed maps of a conscious animal's brain activity, a state that much better represents the human condition.

"The rat models created by SAGE Labs have been genetically modified to reflect patient-relevant mutations and exhibit highly relevant, robust phenotypes. The combination of these rats with Ekam's imaging platform presents a transformative opportunity for translational neuroscience programs. Ultimately, these types of studies will lead to better drugs targeting neurodegenerative diseases such as Parkinson's and Alzheimer's diseases," said Edward Weinstein, Ph.D., Director of SAGE Labs.

"Probing the brain functions of a conscious animal, specifically in rats which are prized by the neuroscience community for intelligence and complex social behaviors, produces data that is much more representative of a potential therapy's effects on human processes," said Mark Nedelman, MS, MBA, President and CEO of Ekam Imaging.

Nedelman's company is currently producing a detailed map of neural activity in SAGE Lab's Pink1 gene knockout rat, which SAGE Labs generated for The Michael J. Fox Foundation to model Parkinson's disease. The Pink1 gene knockout rat exhibits delayed-onset motor deficits, a key phenotype of Parkinson's disease in humans.

Sigma and Ekam plan to publicly launch services specific to SAGE Labs' neuroscience rat models in early 2013.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "more precise," "unambiguously," "curtail," "rapidly" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that preclincal imaging assays or related services will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with preclinical imaging assays or related services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,100 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at http://www.sigma-aldrich.com.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries. SAGE is a registered trademark of Sigma-Aldrich Co. LLC.

Continue reading here:
SAGE® Labs, Ekam Imaging, Inc. Partner to Develop Preclinical Imaging Assays to Screen Therapies of Neurodegenerative ...

3D Biomatrixs Perfecta3D Hanging Drop Plates, which are easy-to-use 96- and 384-well plates for controllable three-dimensional (3D) spheroid culture, were recently featured in several prominent life science and biotechnology journals and websites: Bioscience Technology, The Scientist, Biocompare, and Genetic Engineering and Biotechnology News.

Ann Arbor, MI (PRWEB) September 25, 2012

The Hanging Drop Plates, which allow for controllable 3D spheroid or embryonic stem cell cultures in a well plate format, simplify and streamline spheroid formation, culture, and subsequent testing of the 3D cellular constructs without the aid of coatings or matrices. Such cultures grown in Perfecta3D Hanging Drop Plates allow researchers to easily mimic tissue metabolic and proliferative gradients, capture complex cell-matrix and cell-cell interactions, conduct co-cultures, and monitor cell growth easily and regularly.

In its August issue, Bioscience Technology, a print and online biotechnology magazine, spotlights the Perfecta3D 96-Well Hanging Drop Plates as an Editors Choice technology for new innovative products.

The Scientist, a professional print and online life science magazine that focuses on research news and applications, included the Perfecta3D Hanging Drop Plates in an article in its September 1 issue titled Enter the Third Dimension. The article reviews five innovative tools for 3D cell culture. Of the five tools, the Hanging Drop Plates are the only technology that does not force cell interaction with surfaces or matrices, and also the only technology described as ready for high throughput and automation for drug discovery. The article also quotes University of Michigan Professor Shuichi Takayama, the inventor of the Hanging Drop Plates.

Biocompare, an online resource for life science product information and new technologies, featured the Perfecta3D Hanging Drop Plates in a September 18 article titled, Research Tools for Three-Dimensional Cell Culture. The article describes 3D cell culture technologies in the areas of scaffold-free plates, scaffolds, gels and extracellular matrices, and bioreactors. 3D Biomatrix CEO, Laura Schrader, was quoted in the article.

3D Biomatrix published a Tech Note in the September 15 issue of Genetic Engineering and Biotechnology News titled, 3D Spheroid Models Enter Screening Toolbox. Genetic Engineering and Biotechnology News is a prominent biotechnology newsletter. The Tech Note describes the Perfecta3D Hanging Drop Plates, their applications, and published data in drug testing and co-cultures.

The recent prevalence of articles focusing on 3D cell culture tools demonstrates the growing number of researchers and companies recognizing the importance of 3D cell culture, says Schrader. We are delighted to be included in these articles, as it demonstrates that the Perfecta3D Hanging Drop Plates are becoming prolific on the market because they are easy to adopt and offer a realistic 3D environment.

More information on the Perfecta3D Hanging Drop Plates and direct links to the articles featuring the plates can be found on the 3D Biomatrix website.

Meghan Cuddihy 3D Biomatrix 734.272.4688 Email Information

Originally posted here:
3D Biomatrix’s Perfecta3D® Hanging Drop Plates Featured in Prominent Life Science Journals

Public release date: 21-Aug-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 21, 2012For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com) The article is available free online at the BioResearch Open Access website (http://www.liebertpub.com/biores).

Pancreatic stem cells, the precursors of insulin-producing cells, have not yet been identified in humans or animals, and there is much debate about where they may reside. Ivka Afrikanova, Ayse Kayali, Ana Lopez, and Alberto Hayek, University of California, San Diego, CA, have identified a biochemical markerstage-specific embryonic antigen 4 (SSEA4)that they propose can be used to identify and purify human pancreatic stem cells. The article "Is Stage-Specific Embryonic Antigen 4 a Marker for Human Ductal Stem/Progenitor Cells" (http://online.liebertpub.com/doi/full/10.1089/biores.2012.0235) reports that when grown in culture with high levels of glucose and B27, these SSEA4+ stem cells can differentiate into insulin-producing pancreatic cells.

###

About the Journal

BioResearch Open Access (http://www.liebertpub.com/biores) is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available online at the BioResearch Open Access website (http://www.liebertpub.com/biores).

About the Publisher

Mary Ann Liebert, Inc., publishers (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website (http://www.liebertpub.com).

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

Originally posted here:
New marker for identifying precursors to insulin-producing cells in pancreas

Public release date: 13-Aug-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, August 13, 2012Even after being frozen for 18 years, human embryos can be thawed, grown in the laboratory, and successfully induced to produce human embryonic stem (ES) cells, which represent a valuable resource for drug screening and medical research. Prolonged embryonic cryopreservation as an alternative source of ES cells is the focus of an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc. The article is available free online at the BioResearch Open Access website.

Kamthorn Pruksananonda and coauthors from Chulalongkorn University and Chulalongkorn Memorial Hospital, Bangkok, Thailand, demonstrated that ES cells derived from frozen embryos have a similar ability to differentiate into multiple cell typesa characteristic known as pluripotencyas do ES cells derived from fresh embryos. They present their findings in the article "Eighteen-Year Cryopreservation Does Not Negatively Affect the Pluripotency of Human Embryos: Evidence from Embryonic Stem Cell Derivation."

"The importance of this study is that it identifies an alternative source for generating new embryonic stem lines, using embryos that have been in long-term storage," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available online at the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at the Mary Ann Liebert, Inc. website.

See original here:
Human embryos frozen for 18 years yield viable stem cells suitable for biomedical research